Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SELP | P16109 | 2/20 | 0.73 |
| ▸ | SELL | P14151 | 1/20 | 0.73 |
| ▸ | SIGLEC7 | Q9Y286 | 6/20 | 0.62 |
| ▸ | SELE | P16581 | 5/20 | 0.61 |
| ▸ | MAG | P20916 | 6/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13195877 | 1.00 | SELP (0.73) | SELPSELLSIGLEC7SELEMAG | |
| SCHEMBL29405702 | 1.00 | SELP (0.73) | SELPSELLSIGLEC7SELEMAG | |
| SCHEMBL13978771 | 1.00 | SELP (0.73) | SELPSELLSIGLEC7SELEMAG | |
| SCHEMBL29389517 | 1.00 | SELP (0.73) | SELPSELLSIGLEC7SELEMAG | |
| SCHEMBL29448496 | 1.00 | SELP (0.73) | SELPSELLSIGLEC7SELEMAG | |
| SCHEMBL29391699 | 1.00 | SELP (0.73) | SELPSELLSIGLEC7SELEMAG | |
| SCHEMBL29407985 | 0.99 | SELP (0.71) | SELPSELLSIGLEC7SELEMAG | |
| SCHEMBL29466129 | 0.98 | SELP (0.70) | SELPSELLSIGLEC7SELEMAG | |
| SCHEMBL29466139 | 0.98 | SELP (0.70) | SELPSELLSIGLEC7SELEMAG | |
| SCHEMBL31010809 | 0.96 | SELP (0.71) | SELPSELLSIGLEC7SELEMAG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 185 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4731778-A2 | SIALYLTRANSFERASES FOR THE PRODUCTION OF SIALYLATED OLIGOSACCHARIDES | Inbiose N.V. (BE) | 2026-04-29 | — | — | EP | claimed |
| US-12577308-B2 | Anti-E-selectin antibodies, compositions and methods of use | PFIZER INC. (US) | 2026-03-17 | — | — | US | claimed |
| US-20260062726-A1 | HYBRID METHOD FOR PRODUCING COMPLEX HMOS | DSM IP ASSETS BV (NL) | 2026-03-05 | — | — | US | claimed |
| WO-2025224348-A1 | PRODUCTION OF A MILK OLIGOSACCHARIDE MIXTURE | INBIOSE N.V. (BE) | 2025-10-30 | — | — | WO | claimed |
| EP-4623089-A1 | TWO-STRAIN SYSTEM FOR PRODUCING OLIGOSACCHARIDES | DSM IP Assets B.V. (NL) | 2025-10-01 | — | — | EP | claimed |
| US-20250223649-A1 | COMPOSITIONS AND METHODS FOR DETECTION OF LUNG CANCER | MERCY BIOANALYTICS, INC. | 2025-07-10 | — | — | US | claimed |
| EP-4577061-A1 | HYBRID METHOD FOR PRODUCING COMPLEX HMOS | DSM IP Assets B.V. (NL) | 2025-07-02 | — | — | EP | claimed |
| CN-119735693-A | Proteins binding NKG2D, CD and tumor-associated antigens | 蜻蜓疗法股份有限公司 | 2025-04-01 | — | — | CN | claimed |
| CN-119451692-A | Mass spectrometry method for cancer diagnosis | AOA DX公司 | 2025-02-14 | — | — | CN | claimed |
| EP-4504250-A1 | MASS SPECTROMETRY METHODS FOR CANCER DIAGNOSIS | AOA Dx (US) | 2025-02-12 | — | — | EP | claimed |
| WO-2023133299-A1 | COMPOSITIONS AND METHODS FOR DETECTION OF LUNG CANCER | MERCY BIOANALYTICS, INC. (US) | 2023-07-13 | — | — | WO | claimed |
| WO-2023091618-A1 | COMPOSITIONS AND METHODS FOR DETECTION OF OVARIAN CANCER | MERCY BIOANALYTICS, INC. (US) | 2023-05-25 | — | — | WO | claimed |
| US-11597770-B2 | Anti-E-selectin antibodies, compositions and methods of use | PFIZER INC. (US) | 2023-03-07 | — | — | US | claimed |
| US-20230058412-A1 | Carbohydrate-Modified Particles and Particulate Formulations for Modulating an Immune Response | NORTHWESTERN UNIVERSITY | 2023-02-23 | — | — | US | claimed |
| US-11576957-B2 | Vaccine and therapeutic compositions comprising antigen-conjugated viral capsids | BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY (US) | 2023-02-14 | — | — | US | claimed |
| WO-2023004077-A2 | COMPOSITIONS AND METHODS FOR DETECTION OF COLORECTAL CANCER | MERCY BIOANALYTICS, INC. (US) | 2023-01-26 | — | — | WO | claimed |
| WO-2023004080-A2 | COMPOSITIONS AND METHODS FOR DETECTION OF PANCREATIC CANCER | MERCY BIOANALYTICS, INC. (US) | 2023-01-26 | — | — | WO | claimed |
| WO-2023004078-A2 | COMPOSITIONS AND METHODS FOR DETECTION OF BREAST CANCER | MERCY BIOANALYTICS, INC. (US) | 2023-01-26 | — | — | WO | claimed |
| WO-2023004087-A2 | COMPOSITIONS AND METHODS FOR CANCER DETECTION | MERCY BIOANALYTICS, INC. (US) | 2023-01-26 | — | — | WO | claimed |
| WO-2022264171-A1 | HEXOSAMINE COMPOUNDS AND METHODS THEREOF | NATIONAL INSTITUTE OF IMMUNOLOGY (IN) | 2022-12-22 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11597770-B2 | Anti-E-selectin antibodies, compositions and methods of use | SELE, SELP, SELL | SELP 2/4885SELL 3/4885SIGLEC7 10/4885 |
| US-12577308-B2 | Anti-E-selectin antibodies, compositions and methods of use | FCGR3B, FCGR2A, SELL | SELP 13/4885SELL 3/4885SIGLEC7 29/4885 |
| US-20260062726-A1 | HYBRID METHOD FOR PRODUCING COMPLEX HMOS | FUCA1, GMDS, MANBA | SELP 2667/4885SELL 2472/4885SIGLEC7 474/4885 |
| US-11576957-B2 | Vaccine and therapeutic compositions comprising antigen-conjugated viral capsids | TP53, MAPT, SPAG5 | SELP 3042/4885SELL 3644/4885SIGLEC7 461/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.